Water-soluble geldanamycin analog, Alvespimycin

17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG, also known as NSC 707545) is the first water-soluble analog of 17-AAG. This Hsp90 inhibitor shows promise in preclinical models [1]. 17-DMAG has excellent bioavailability, is widely distributed to tissues, and is quantitatively metabolized much less than is 17-AAG [2]. Clinical studies have shown that alvespimycin (KOS-1022) has therapeutic effects and is well tolerated in patients with solid tumours, advanced solid tumours or acute myeloid leukaemia, indicating that it has potential to be a new drug of choice for cancer therapy.


CAS number: 467214-21-7

Formula: C32H48N4O8, HCl

Molecular weight: 653.2

Solubility: H2O (10 mg/ml)


- 5 mg or 25 mg


1. Workman P., 2003. Overview: translating Hsp90 biology into Hsp90 drugs.Curr Cancer Drug Targets 3(5):297-300.
2. Egorin MJ, et al., 2002.Pharmacokinetics, tissue distribution, and metabolism of 17- (dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49(1):7-19.



Cat. Codeant-dgl-5
Unit Size5 mg
Price For price or distributor address,
please select your country


Cat. Codeant-dgl-25
Unit Size25 mg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".